

References

- Arthur**, C.Gwyton, MD text book of medical physiology 9th edition .USA 2000
Page (420-425).
- Bishop**, M.L, Engel Kirk, J.Land fody, E.P clinical chemistry principles, correlations 5th
edition Lippincott Williams and Wilkins 2000 page (444).
- Bishop**, M.L, fody, E.Pand schoeff.L.E. Clinical chemistry techniques principles,
correlations wolters kluwery, 6th edition Lippincott and Wilkins 1985 page 272.
- Bishop**, M.L, fody, E.Pand schoeff.L.Eclinical chemistry techniques principles,
correlations wolters kluwery, 6th edition Lippincott and Wilkins 1985
Pages (556-560).
- Bleyer** AJ (2003): phosphate binder usage in kidney failure patients: Expert Opin
pharmacother.4:941-947.
- Block** GA, Klasses Ps, Lazarus JM, et al (2004): mineral metabolism, mortality, and
morbidity in maintenance hemodialysis. J Am Soc Nephrol.15:2208-2218.
- Bushinky**, D.A, Monk RD.Calcium.Lancet 1998; 352:23.
- Coresh J**, Astor BC, GreeneT, et al (2003): prevalence of chronic kidney disease and
decreased kidney function in the adult US population: Third National Health and
Nutrition Examination Survey. J Am Kid Dis., 41:1-12.
- Gamst**, O.B and Try K.Determination of serum-phosphate without deproteinization by
ultraviolet spectrophotometry of the phosphomolybdic acid complex .Scand J Clin Lab
Invest 1980, 40:483-486.
- Jacob**, S.T, atlas of human anatomy Churchill ST Louis Sydney Toronto 6th edition 2002
pages (128-134).
- K.Lorentz**. Improved determination of serum calcium with Aresenazo III.clinical
chemistry Acta 1982, 126:327-334.
- Levin** A and LiYc (2005): Vitamin D and its analogues: do they protect against
cardiovascular disease in patients with kidney disease. Kid Int.68:1973-1981.
- Malluche** HH, Mawada H and Monier –Faugere MC (2004): The importance of bone
health in end- stage renal disease Nephrol.i9-i13.

Marshall, W.J and Bangert .S.K clinical chemistry Mosby Edinburgh London New York oxford philaderhia ST Louis Sydney Toronto 5th edition, 2004
Page (184-287).

Mayn, Z.P, clinical chemistry in Diagnosis and treatment Arnold, London.
Sydney Auckland co-published in the USA by oxford university press, Inc, new York 5th edition 1994, page (2-4).

Mayn, Z.P, clinical chemistry in Diagnosis and treatment Arnold, London. Sydney Auckland co-published in the USA by oxford university press, Inc, New York 6th edition 1994 pages (173-183).

Norbert, W.T.tietz fundamentals of clinical chemistry 5th edition .USA 2001 page (699, 712-720).

Ramink sood, text book of medical laboratory technology, Jaypee brothers, 2006
Page 649.

Ridge, B.B, human physiology, higher Education ,Boston Burr Ridge, IL Dubuque ,IA Madison 9th edition ,2006 pages (551-552).

Shiber, J.R, Mattu A. Serum phosphate abnormalities in the emergency department JEmerg Med 2002; 23:395-400.

Slatopalsky E, Brown A, and Dusso A (1999): pathogenesis of secondary hyperparathyroidism. Kid Int .Suppl 73:S14-S19.

Thomas L. Clinical Laboratory Diagnostics. 1st ed. Frankfurt : TH-Books Verlagsgesellschaft; 1998.

Tietz, N.W, fundamentals of clinical chemistry W.B.saunders Company third edition 1987 pages (684-686).

SUDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY
Measurement of Serum Uric Acid, phosphate and Calcium Pre and
Post Hemodialysis

A-General information:

1-Name:
2-Age:4-Residence.....
3-Gender:5-Occupation.....

B-Clinical information:

1-Duration of disease

2-exclusion Factors:

Cardiac disease

Gout.....

Hypertension.....

Diabetes Mellitus.....

3-Type of Dialysis:

Haemodylsis.....

Peritoneal.....

4-Interval of dialysis per week:

C-laboratory investigations:

Serum.....

